Iinkcukacha zajikelele
I-Human epidermal growth factor receptor 2 (HER2), eyaziwa ngokuba yi-ErbB2, NEU, kunye ne-CD340, luhlobo lwe-membrane ye-membrane ye-glycoprotein kwaye iyingxenye ye-epidermal growth factor (EGF) yosapho lwe-receptor.Iprotheyini ye-HER2 ayinakubopha izinto zokukhula ngenxa yokunqongophala kwe-ligand binding domain yayo kunye ne-autoinhibited constitutively.Nangona kunjalo, i-HER2 yenza i-heterodimer kunye namanye amalungu osapho lwe-EGF ye-receptor ye-ligand, ngoko ke izinza i-ligand ibophe kwaye ikhulise ukusebenza kwe-kinase-mediated ye-molecules ezantsi.I-HER2 idlala indima ephambili kuphuhliso, ukwanda kweeseli kunye nokwahlulahlula.I-HER2 yofuzo iye yaxelwa ukuba idibanise ne-malignancy kunye ne-prognosis embi kwii-carcinomas ezininzi, kuquka isifuba, i-prostate, i-ovarian, i-cancer ye-lung njalo njalo.
Izindululo ezimbini | I-CLIA (Thatha-Ukufunyanwa): 14-2 ~ 15-6 15-6~ 2-10 |
Ubunyulu | >95%, igqitywe yiSDS-PAGE |
Ukuqulunqwa kwesithinteli | PBS, pH7.4. |
Ugcino | Yigcine phantsi kweemeko ezingakhuselekanga ku -20℃ ukuya -80℃ xa uyifumene. Ncoma ukuba i-aliquot iprotheni ibe yimiyinge emincinci yokugcina eyona ilungileyo. |
Igama lemveliso | Ikati.Hayi | Clone ID |
Her2 | AB0078-1 | 14-2 |
AB0078-2 | 15-6 | |
AB0078-3 | 2-10 |
Qaphela: I-Bioantibody inokuhlengahlengiswa ngokwemfuno yakho.
1.Krawczyk N, et al.(2009) ubume be-HER2 kwiiseli zethumba ezisasazwayo emva konyango lwe-adjuvant lunokwahluka kwisimo sokuqala se-HER2 kwithumba eliphambili.I-Anticancer Res.29(10): 4019-24.